Brief: Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation To Provide Increased Funding And Support For Elx-02 Global Phase 2 Clinical Trial Program
13/01/2021 15:23
Jan 13 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES CYSTIC FIBROSIS FOUNDATION
(CF
FOUNDATION) TO PROVIDE INCREASED FUNDING AND SUPPORT FOR ELX-02
GLOBAL PHASE 2 CLINICAL TRIAL PROGRAM
* ELOXX PHARMACEUTICALS INC - EXPECT TO REPORT TOP LINE DATA
FROM
OUR PHASE 2 CYSTIC FIBROSIS CLINICAL TRIAL PROGRAM FOR ELX-02 IN
FIRST HALF OF 2021
Source text for Eikon: ID:nGNX21qJPb
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome